View More Recent Stories
-
BTIG Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
LifeSci Capital Starts Liquidia Technologies (LQDA) at Outperform
-
Liquidia Technologies (LQDA) Reports Court Found United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of over $137M
-
Liquidia Technologies (LQDA) Raises $67.5M from Share Sales, $32.5M Advance from HealthCare Royalty Under Current Financing Agreement
-
Liquidia Technologies (LQDA) Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA inhalation powder for Patients Suffering with PAH and PH-ILD
-
Liquidia Technologies (LQDA) PT Lowered to $29 at H.C. Wainwright
-
Liquidia Technologies (LQDA) PT Lowered to $23 at BofA Securities
-
United Therapeutics Corp. (UTHR) PT Raised to $380 at Wells Fargo
-
Goldman Sachs Reiterates Neutral Rating on United Therapeutics Corp. (UTHR)
-
Liquidia Technologies (LQDA) PT Lowered to $17 at Jefferies
-
Liquidia Technologies (LQDA) PT Lowered to $25 at BTIG
-
Midday movers: Estee Lauder, HP Inc fall; AMD rises
-
Liquidia Technologies (LQDA) Granted FDA Tentative Approval for YUTREPIA
-
Liquidia Technologies (LQDA) Announces Poster Presentations at the PHA 2024 International
-
Liquidia Corporation (LQDA) Misses Q2 EPS by 3c
-
H.C. Wainwright Reiterates Buy Rating on Liquidia Technologies (LQDA)
-
Liquidia Technologies (LQDA) Files for 7.32M Share Offering by Selling Stockholders
-
Liquidia Technologies (LQDA) at the money July 12.50 and August 12.50 call spreads as share price pulls back to 6-month low

